You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

Citation Tools

Article menu

Download PDFPDF

XML
Research Article
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Tran B, Carvajal RD, Marabelle A, et al
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer 2018;6:93. doi: 10.1186/s40425-018-0407-x